The outcome and safety of re-challenge Lutetium-177 PSMA (177Lu-PSMA) therapy with Low-Dose Docetaxel as a Radiosensitizer—a promising combination in metastatic castrate-resistant prostate cancer (mCRPC) : a case report
- UPSpace Home
- →
- Health Sciences
- →
- Nuclear Medicine
- →
- Research Articles (Nuclear Medicine)
- →
- View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.
| dc.contributor.author | Maharaj, Masha
|
|
| dc.contributor.author | Heslop, Lucille
|
|
| dc.contributor.author | Govender, Trisha
|
|
| dc.contributor.author | Korowlay, Nisaar
|
|
| dc.contributor.author | Singh, Aviral
|
|
| dc.contributor.author | Choudhary, Partha
|
|
| dc.contributor.author | Sathekge, Mike Machaba
|
|
| dc.date.accessioned | 2022-02-14T05:25:36Z | |
| dc.date.issued | 2021-06 | |
| dc.description.abstract | Please read abstract in the article. | en_ZA |
| dc.description.department | Nuclear Medicine | en_ZA |
| dc.description.embargo | 2022-04-13 | |
| dc.description.librarian | hj2022 | en_ZA |
| dc.description.uri | https://link.springer.com/journal/13139 | en_ZA |
| dc.identifier.citation | Maharaj, M., Heslop, L., Govender, T. et al. The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer—a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report. Nuclear Medicine and Molecular Imaging 55, 136–140 (2021). https://doi.org/10.1007/s13139-021-00696-5. | en_ZA |
| dc.identifier.issn | 1869-3474 (print) | |
| dc.identifier.issn | 1869-3482 (online) | |
| dc.identifier.other | 10.1007/s13139-021-00696-5 | |
| dc.identifier.uri | http://hdl.handle.net/2263/83831 | |
| dc.language.iso | en | en_ZA |
| dc.publisher | Springer | en_ZA |
| dc.rights | © Korean Society of Nuclear Medicine 2021. The original publication is available at : https://link.springer.com/journal/13139. | en_ZA |
| dc.subject | Prostate-specific membrane antigen (PSMA) | en_ZA |
| dc.subject | Lutetium-177 (177Lu) | en_ZA |
| dc.subject | Docetaxel | en_ZA |
| dc.subject | Prostate cancer | en_ZA |
| dc.subject | Radiosensitizer | en_ZA |
| dc.subject | Re-challenge | en_ZA |
| dc.subject | Radioligand therapy (RLT) | en_ZA |
| dc.subject | Metastatic castrate-resistant prostate cancer (mCRPC) | en_ZA |
| dc.title | The outcome and safety of re-challenge Lutetium-177 PSMA (177Lu-PSMA) therapy with Low-Dose Docetaxel as a Radiosensitizer—a promising combination in metastatic castrate-resistant prostate cancer (mCRPC) : a case report | en_ZA |
| dc.type | Postprint Article | en_ZA |
